Elan drug Tysabri gets EC go-ahead
Elan Corporation plc and Biogen Idec today announced that they received approval from the European Commission to market Tysabri as a treatment for multiple sclerosis (MS).
The drug delays the progression of the disability and reduces the frequency of relapses.
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.





